The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars

Frontiers in Psychology

article

Davide Mazzoni¹  Claudia Vener¹  Ketti Mazzocco¹  Dario Monzani¹  Gabriella Pravettoni¹ 

[1] Department of Oncology and Hemato-Oncology, University of Milan;Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology IRCCS

关键词: nocebo effect;    shared decision-making;    adherence;    rheumatology;    oncology;   

DOI  :  10.3389/fpsyg.2021.605643

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Biological products are therapeutic agents produced using a living system or organism. In manycases, access to these products is limited due to their expensive cost (Chow et al., 2011). A biosimilaris a biological product that is highly similar (not identic) to, and has no clinically meaningfuldifferences from, an existing reference biological product on the market (Desai et al., 2020).“Non-medical” switching is the switching of a patient’s medicine for reasons other than the patient’shealth and safety, like the reduction of costs (Dolinar et al., 2019).

【 授权许可】

CC BY